Search Criteria:
Title/Abstract: HAART and HIV **In Journals:** J. Virol.

Results are shown in relevance ranked order. **To rephrase your existing search criteria**, press the "Back" button on your browser. [Help with Searching]

Search Results

Results 1 to 10 (of 17 found)
[View Next 7 Results]

To see an article, click its [Full Text] or [PDF] link. **To review many abstracts**, check the boxes to the left of the titles you want and click the "Get All Checked Abstract(s)" button. **To see one abstract at a time**, click its [Abstract] link.

Clear | Get All Checked Abstract(s)

☐ B. E. Palmer, E. Boritz, N. Blyveis, and C. C. Wilson
Discordance between Frequency of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Gamma Interferon-Producing CD4+ T Cells and HIV-1-Specific Lymphoproliferation in HIV-1-Infected Subjects with Active Viral Replication
J. Virol. 2002 76: 5925-5936. [Abstract] [Full Text] [PDF]

☐ Tuofu Zhu, David Muthui, Sarah Holte, David Nickle, Feng Feng, Scott Brodie, Yon Hwangbo, James I. Mullins, and Lawrence Corey
Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy
J. Virol. 2002 76: 707-716. [Abstract] [Full Text] [PDF]

☐ Guislaine Carcelain, Roland Tubiana, Assia Samri, Vincent Calvez, Constance Delaugerre, Henri Agut, Christine Katlama, and Brigitte Autran
Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection
J. Virol. 2001 75: 234-241. [Abstract] [Full Text] [PDF]

☐ Monika Hermankova, Janet D. Siliciano, Yan Zhou, Daphne Monie, Karen Chadwick, Joseph B. Margolick, Thomas C. Quinn, and Robert F. Siliciano
Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4+ T Lymph cytes In Vivo
J. Virol. 2003 77: 7383-7392. [Abstract] [Full Text] [PDF]

☐ Wei Lu and Jean-Marie Andrieu
In Vitro Human Immunodeficiency Virus Eradicati n by Autol g us CD8+ T Cells Expanded with Inactivated-Virus-Pulsed Dendritic Cells

J. Virol. 2001 75: 8949-8956. [Abstract] [Full Text] [PDF]

☐ Joseph P. Casazza, Michael R. Betts, Louis J. Picker, and Richard A. Koup

Decay Kinetics f Human Immunodeficiency Virus-Specific CD8+ T Cells in Peripheral Blood after Initiation of Highly Active Antiretr viral Therapy

J. Virol. 2001 75: 6508-6516. [Abstract] [Full Text] [PDF]

☐ Lisa M. Frenkel, Yang Wang, Gerald H. Learn, Jennifer L. McKernan, Giovanina M. Ellis, Kathleen M. Mohan, Sarah E. Holte, Shannon M. De Vange, Diane M. Pawluk, Ann J. Melvin, Paul F. Lewis, Laura M. Heath, Ingrid A. Beck, Madhumita Mahalanabis, Wilscott E. Naugler, Nicole H. Tobin, and James I. Mullins

Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy

J. Virol. 2003 77: 5721-5730. [Abstract] [Full Text] [PDF]

☐ Mark Dybul, Marybeth Daucher, Mark A. Jensen, Claire W. Hallahan, Tae-Wook Chun, Michael Belson, Bertha Hidalgo, David C. Nickle, Christian Yoder, Julia A. Metcalf, Richard T. Davey, Linda Ehler, Diane Kress-Rock, Elizabeth Nies-Kraske, Shuying Liu, James I. Mullins, and Anthony S. Fauci

Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy

J. Virol. 2003 77: 3229-3237. [Abstract] [Full Text] [PDF]

☐ John Wilkinson, Alethea Cope, Jas Gill, Dimitra Bourboulia, Peter Hayes, Nesrina Imami, Toru Kubo, Anne Marcelin, Vincent Calvez, Robin Weiss, Brian Gazzard, Chris Boshoff, and Frances Gotch

Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy

J. Virol. 2002 76: 2634-2640. [Abstract] [Full Text] [PDF]

☐ Yael D. Korin, David G. Brooks, Stephen Brown, Andrew Korotzer, and Jerome A. Zack

Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency

J. Virol. 2002 76: 8118-8123. [Abstract] [Full Text] [PDF]

Clear | Get All Checked Abstract(s)

To see an article, click its [Full Text] or [PDF] link. **To review many abstracts**, check the boxes to the left of the titles you want and click the "Get All Checked Abstract(s)" button. **To see one abstract at a time**, click its [Abstract] link.

[View Next 7 Results]

Try this search in: Please select a journal: Search

Search Criteria:

Title/Abstract: HAART and HIV **In J urnals:** J. Virol.

Search Criteria:
Title/Abstract: HAART and HIV **In Journals:** J. Virol.

Results are shown in relevance ranked order. **To rephrase your existing search criteria**, press the "Back" button on your browser. [Help with Searching]

Search Results

Results 11 to 17 (of 17 found)
[View Previous 10 Results]

To see an article, click its [Full Text] or [PDF] link. **To review many abstracts**, check the boxes to the left of the titles you want and click the "Get All Checked Abstract(s)" button. **To see one abstract at a time**, click its [Abstract] link.

Clear | Get All Checked Abstract(s)

☐ Xia Jin, Murugappan Ramanathan, Jr., Shady Barsoum, Geoffrey R. Deschenes, Lei Ba, James Binley, Daryl Schiller, Daniel E. Bauer, Donald C. Chen, Arlene Hurley, Lucette Gebuhrer, Raphaelle El Habib, Pierre Caudrelier, Michel Klein, Linqi Zhang, David D. Ho, and Martin Markowitz

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

J. Virol. 2002 76: 2206-2216. [Abstract] [Full Text] [PDF]

☐ Christian T. Ruff, Stuart C. Ray, Patricia Kwon, Rebekah Zinn, Amanda Pendleton, Nancy Hutton, Roxann Ashworth, Stephen Gange, Thomas C. Quinn, Robert F. Siliciano, and Deborah Persaud

Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure

J. Virol. 2002 76: 9481-9492. [Abstract] [Full Text] [PDF]

☐ Spyros A. Kalams, Philip J. Goulder, Amy K. Shea, Norman G. Jones, Alicja K. Trocha, Graham S. Ogg, and Bruce D. Walker

Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy

J. Virol. 1999 73: 6721-6728. [Abstract] [Full Text] [PDF]

☐ Hugues Thiebot, Fawzia Louache, Bruno Vaslin, Thierry de Revel, Olivier Neildez, Jérome Larghero, William Vainchenker, Dominique Dormont, and Roger Le Grand

Early and Persistent Bone Marr w Hematopoiesis Defect in Simian/Human Immunodeficiency Virus-Infected Macaques despite Efficient Reducti n f Viremia by Highly Active Antiretr viral Therapy during Primary Infection

J. Virol. 2001 75: 11594-11602. [Abstract] [Full Text] [PDF]

☐ David C. Montefiori, Tanya S. Hill, Ha T. T. Vo, Bruce D. Walker, and Eric S. Rosenberg
Neutralizing Antibodies Associated with Viremia Control in a Subset of Individuals after Treatment of Acute Human Immunodeficiency Virus Type 1 Infection
J. Virol. 2001 75: 10200-10207. [Abstract] [Full Text] [PDF]

☐ Jennifer M. Babik and Mark Holodniy
Impact of Highly Active Antiretroviral Therapy and Immunologic Status on Hepatitis C Virus Quasispecies Diversity in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
J. Virol. 2003 77: 1940-1950. [Abstract] [Full Text] [PDF]

☐ Gabriel M. Ortiz, Jennifer Hu, Joshua A. Goldwitz, Rohit Chandwani, Marie Larsson, Nina Bhardwaj, Sebastian Bonhoeffer, Bharat Ramratnam, Linqi Zhang, Martin M. Markowitz, and Douglas F. Nixon
Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8$^+$ T-Cell Responses in Subjects Treated Early after Infection
J. Virol. 2002 76: 411-415. [Abstract] [Full Text] [PDF]

Clear | Get All Checked Abstract(s)

To see an article, click its [Full Text] or [PDF] link. **To review many abstracts**, check the boxes to the left of the titles you want and click the "Get All Checked Abstract(s)" button. **To see one abstract at a time**, click its [Abstract] link.

[View Previous 10 Results]

Try this search in: Please select a journal: Search

Search Criteria:
Title/Abstract: HAART and HIV **In Journals:** J. Virol.

WEST Search History

DATE: Tuesday, July 01, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,JPAB,EPAB,DWPI; PLUR=YES; OP=OR			
L14	L13	52	L14
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR			
L13	L12 and pegylat$	204	L13
L12	((interferon or IFN) with (alpha-2a or alpha-2b) or IFN-alpha2a or IFN-alpha2b)	503	L12
L11	(5759842 5951974 6124327).pn.	6	L11
L10	L7 and ((interferon or IFN) with (alpha-2a or alpha-2b) or IFN-alpha2a or IFN-alpha2b)	11	L10
L9	L8 and (hepatitis$)	16	L9
L8	L5 and (interferon near alpha$3 or interferon-alpha$3).clm.	26	L8
L7	L5 and (interferon near alpha$3 or interferon-alpha$3)	204	L7
L6	L5 and (interferon adj alpha$3 or interferon-alpha$3)	204	L6
L5	L3 and interferon$ with Hiv$2	204	L5
L4	(interferon-alpha or interferon adj alpha) with (2a or 2b) same HIV-1	6	L4
L3	(interferon adj alpha$3 or interferon-alpha$3 or interferon adj alpha adj (2a or 2b)) same HIV$2	293	L3
L2	(interferon adj alpha$3 or interferon-alpha$3 or interferon adj alpha adj (2a or 2b)) and HIV$2	1866	L2
DB=USPT; PLUR=YES; OP=OR			
L1	(interferon adj alpha$3 or interferon-alpha$3 or interferon adj alpha adj (2a or 2b)) and HIV$2	1039	L1

END OF SEARCH HISTORY

STN Search History

FILE 'HOME' ENTERED AT 18:37:37 ON 01 JUL 2003

L1 4062 (INTERFERON ADJ ALPHA OR INF-ALPHA OR INTERFERON-ALPHA OR INF ADJ ALPHA) AND (HIV OR AIDS OR IMMUNODEFICIENCY OR HIV-1)

L2 2223 (INTERFERON ADJ ALPHA OR INF-ALPHA OR INTERFERON-ALPHA OR INF ADJ ALPHA) (S) (HIV OR AIDS OR IMMUNODEFICIENCY OR HIV-1)

L3 2909 (INTERFERON (A) ALPHA OR INF-ALPHA OR INTERFERON-ALPHA OR INF (A) ALPHA) (S) (HIV OR AIDS OR IMMUNODEFICIENCY OR HIV-1)

L8 77 L3 AND (HAART OR HIGHLY (A) ACTIVE (A) (ANTIRETROVIRAL OR ANTI-RETROVIRAL) (A) THERAPY)

L17 3458 (INTERFERON (3N) ALPHA) (S) (HIV OR AIDS OR IMMUNODEFICIENCY OR HIV

L21 10773 (INTERFERON) (S) (HIV OR AIDS OR IMMUNODEFICIENCY OR HIV-1)

L22 5279 L21 AND (PEG OR PEGYLAT#### OR CTL OR NK OR LYMPHOCYTE OR T (A) CELL OR T-CELL)

L24 701 L23 AND INTERFERON (S) (COMBINATION OR HAART OR ANTIVIRAL OR ANTIRETROVIRAL)

L26 183 L25 AND INTERFERON (S) (TREATMENT OR THERAPY OR ADMINIS#######)

(FILE 'HOME' ENTERED AT 18:37:37 ON 01 JUL 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 18:38:16 ON 01 JUL 2003

L1 4062 S (INTERFERON ADJ ALPHA OR INF-ALPHA OR INTERFERON-ALPHA OR INF
L2 2223 S (INTERFERON ADJ ALPHA OR INF-ALPHA OR INTERFERON-ALPHA OR INF
L3 2909 S (INTERFERON (A) ALPHA OR INF-ALPHA OR INTERFERON-ALPHA OR INF
L4 990 S L3 AND (CTL OR NK OR LYMPHOCYTE OR T (A) CELL OR T-CELL)
L5 50 S L3 AND (PEG OR PEGYLAT####)
L6 15 S L5 AND L4
L7 7 DUP REM L6 (8 DUPLICATES REMOVED)
L8 77 S L3 AND (HAART OR HIGHLY (A) ACTIVE (A) (ANTIRETROVIRAL OR AN
L9 43 DUP REM L8 (34 DUPLICATES REMOVED)
L10 12 S L9 AND L5
L11 10 S L10 NOT L7
L12 2563 S L3 NOT PY>2000
L13 856 S L12 AND L4
L14 8 S L12 AND L5
L15 7 DUP REM L14 (1 DUPLICATE REMOVED)
L16 4 S L15 NOT (L11 OR L7)
L17 3458 S (INTERFERON (3N) ALPHA) (S) (HIV OR AIDS OR IMMUNODEFICIENCY
L18 54 S L17 AND (PEG OR PEGYLAT####)
L19 37 DUP REM L18 (17 DUPLICATES REMOVED)
L20 17 S L19 NOT (L7 OR L11 OR L16)
L21 10773 S (INTERFERON) (S) (HIV OR AIDS OR IMMUNODEFICIENCY OR HIV-1)
L22 5279 S L21 AND (PEG OR PEGYLAT#### OR CTL OR NK OR LYMPHOCYTE OR T
L23 3991 S L22 NOT PY>2000
L24 701 S L23 AND INTERFERON (S) (COMBINATION OR HAART OR ANTIVIRAL OR
L25 340 DUP REM L24 (361 DUPLICATES REMOVED)
L26 183 S L25 AND INTERFERON (S) (TREATMENT OR THERAPY OR ADMINIS#####
L27 73 S L26 AND L3

L7 ANSWER 1 OF 7 MEDLINE DUPLICATE 1
AN 2003086386 MEDLINE
DN 22485890 PubMed ID: 12598770
TI Perforin expression in **T cells** and virological response to **PEG**-interferon alpha2b in HIV-1 infection.
AU Portales Pierre; Reynes Jacques; Rouzier-Panis Regine; Baillat Vincent; Clot Jacques; Corbeau Pierre
CS Laboratoire d'Immunologie, Hopital Saint Eloi, Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier, France.
SO AIDS, (2003 Mar 7) 17 (4) 505-11.
Journal code: 8710219. ISSN: 0269-9370.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 200304
ED Entered STN: 20030225
Last Updated on STN: 20030430
Entered Medline: 20030429
AB OBJECTIVE AND DESIGN: **Interferon alpha** (IFNalpha), which is known to directly inhibit the **HIV-1** replicative cycle and to increase the activity of cytotoxic T **lymphocytes** (**CTL**), is being tested as an anti-**HIV** agent. As **CTL** play a major role in immune defence against HIV, we wanted to further characterize **CTL** activity and the effect of IFNalpha on it. METHODS: We followed by flow cytometry the intracellular expression of the key mediator of cytotoxicity, perforin, in peripheral blood **T cells** of patients treated with IFNalpha. RESULTS: We observed that the percentage of **T cells** harbouring perforin was higher in infected subjects than in non-infected controls. Administration of IFNalpha2b attached to polyethylene glycol increased this perforin expression further and reduced viral load (P = 0.010). The increase in the percentage of **T cells** expressing perforin correlated with IFNalpha-induced decrease in viral load (r, 0.753; P = 0.003). In addition, the level of perforin expression before IFNalpha administration was inversely correlated with viral load remaining after IFNalpha administration (r, -0.647; P= 0.017). CONCLUSION: The pre-therapeutic percentage of perforin-positive **T cells** might be a predictive marker of the virological response to IFNalpha in HIV-1-infected patients.

L7 ANSWER 2 OF 7 MEDLINE DUPLICATE 2
AN 2003086385 MEDLINE
DN 22485889 PubMed ID: 12598769
TI **Interferon-alpha** restores **HIV**-induced alteration of natural killer cell perforin expression in vivo.
AU Portales Pierre; Reynes Jacques; Pinet Valerie; Rouzier-Panis Regine; Baillat Vincent; Clot Jacques; Corbeau Pierre
CS Laboratoire d'Immunologie, Hopital Saint Eloi, the Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier, France.
SO AIDS, (2003 Mar 7) 17 (4) 495-504.
Journal code: 8710219. ISSN: 0269-9370.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 200304
ED Entered STN: 20030225
Last Updated on STN: 20030430
Entered Medline: 20030429

AB OBJECTIVE: The percentage and the activity of natural killer (**NK**) cells are known to be decreased in HIV-infected patients. However, the mechanisms responsible for this **NK** deficiency are poorly understood. Because of the role of **NK** cells in the host defence against microbial infections, this defect contributes to the virus-induced immune deficiency. The aim of the present study was to better understand this defect in order to be able to restore **NK** function in HIV infection. DESIGN AND METHODS: The expression of the cytolytic mediators perforin and granzyme A was analysed by flow cytometry, the lytic activity of peripheral blood **NK** cells of HIV-infected patients was analysed by cytotoxic assay, and the expression of perforin was followed during administration of interferon (IFN)alpha attached to polyethylene glycol (**PEG**)-IFNalpha. RESULTS: The lytic activity and the expression of perforin and granzyme A was low in **NK** cells of infected individuals in comparison with normal control volunteers. In both groups **NK** cytotoxic capacity was linked to perforin expression. The low perforin expression in HIV-infected subjects negatively correlated with HIV RNA plasma level. administration of **PEG**-IFNalpha restored perforin expression even in patients whose viral load was not reduced by this treatment. CONCLUSIONS: These results suggest that HIV-induced **NK** deficiency could be partly mediated by a defect in perforin and granzyme A expression, and that **PEG**-IFNalpha could be used in infected subjects to directly improve their natural immunity in addition to eventually reducing their viraemia.

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2001:676618 CAPLUS
DN 135:225873
TI **HIV**-specific immune response promoted by **interferon**-.**alpha**.
IN Laughlin, Mark A.
PA Schering Corporation, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066132	A2	20010913	WO 2001-US7453	20010308
	WO 2001066132	A3	20020124		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002004584	A1	20020110	US 2001-801980	20010308
	EP 1263457	A2	20021211	EP 2001-922303	20010308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008997	A	20030603	BR 2001-8997	20010308
	NO 2002004255	A	20020906	NO 2002-4255	20020906
PRAI	US 2000-188338P	P	20000309		
	WO 2001-US7453	W	20010308		

AB Use of **interferon**-.**alpha**., e.g., **pegylated interferon** .**alpha**.-2a or 2b for prepn. of a medicament for promotion of an **HIV-1** specific immune response,

e.g., promotion of **HIV-1** specific **T-cells**, in adult and pediatric patients having **HIV-1** infections as well as patients co-infected with **HIV-1** and HCV comprising a therapeutically effective amt. of **pegylated interferon-.alpha.**, e.g., **pegylated interferon .alpha.**-2b is disclosed.

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2001:265599 CAPLUS
DN 134:294522
TI Interferon .alpha. homologues
IN Heinrichs, Volker; Chen, Teddy; Patten, Phillip A.
PA Maxygen, Inc., USA
SO PCT Int. Appl., 209 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025438	A2	20010412	WO 2000-US27781	20001006
	WO 2001025438	A3	20020711		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1238082	A2	20020911	EP 2000-970665	20001006
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003511031	T2	20030325	JP 2001-528590	20001006
PRAI	US 1999-415183	A	19991007		
	WO 2000-US27781	W	20001006		

AB .alpha. Interferon homologues (both nucleic acids and polypeptides) are provided. Compns. including these interferon homolog polypeptides and nucleic acids, recombinant cells comprising said homolog polypeptides and nucleic acids, methods of making the new homologues, antibodies to the new homologues, and methods of using the homologues are provided. Integrated systems comprising the sequences of the nucleic acids or polypeptides are also provided. These interferon .alpha. homologues are useful for inhibiting tumor growth and viral replication, and are also useful for treating autoimmune diseases.

L7 ANSWER 5 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 3
AN 2001:530219 BIOSIS
DN PREV200100530219
TI Effect of HCV viral dynamics on treatment design: Lessons learned from HIV.
AU Bain, Vincent G. (1)
CS (1) Department of Medicine, Division of Gastroenterology, University of Alberta, 8440 112 Street, 2E1.14 WMC, Edmonton, AB, T6G 2R7 Canada
SO American Journal of Gastroenterology, (October, 2001) Vol. 96, No. 10, pp. 2818-2828. print.
ISSN: 0002-9270.
DT Article; General Review
LA English
SL English

AB Viral load measurements provide an indication of viral replication, and thereby serve as a valuable tool to guide the initiation of therapy and subsequent changes. Plasma human **immunodeficiency** viral load strongly predicts the rate of decrease in CD4+ **lymphocyte** count, and progression to **AIDS** and death. Furthermore, the efficacy of antiretroviral therapy can be assessed by monitoring changes in plasma human **immunodeficiency** viral load. Similarly, viral load provides valuable information about the natural history of the hepatitis C virus infection. Hepatitis C viral load can be used to predict the likelihood of response to standard **interferon-alpha** treatment and other **interferon-alpha** regimens and to monitor treatment efficacy. Increased understanding of the natural history of the hepatitis C virus infection and the nature of resistance to **interferon-alpha** therapy suggests that effective treatment regimens must maintain serum levels of **interferon-alpha**. Ideally, **interferon-alpha** serum levels should provide constant pressure on the virus and should prevent viral rebound, thereby avoiding continued viral replication and minimizing the potential for emergence of resistant quasi-species. Current regimens designed to address these points include early aggressive intervention, combination drug regimens, prolonged maintenance, and novel interferons. By enabling the design and rapid assessment of new treatment regimens, viral load measurement will revolutionize the clinical management of the hepatitis C virus infection, as it has the **HIV**.

L7 ANSWER 6 OF 7 MEDLINE
AN 2001457575 MEDLINE
DN 21395681 PubMed ID: 11504966
TI Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and **pegylated** IFN alpha: results from the Primoferon A (ANRS 086) Study.
AU Emilie D; Burgard M; Lascoux-Combe C; Laughlin M; Krzysiek R; Pignon C; Rudent A; Molina J M; Livrozet J M; Souala F; Chene G; Grangeot-Keros L; Galanaud P; Sereni D; Rouzioux C
CS Service de Medecine Interne et d'Immunologie Clinique, Hopital Antoine Beclere, Institut Paris-Sud sur les Cytokines, Clamart, France. (Primoferon A Study Group).
SO AIDS, (2001 Jul 27) 15 (11) 1435-7.
Journal code: 8710219. ISSN: 0269-9370.
CY England: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
LA English
FS Priority Journals; AIDS
EM 200109
ED Entered STN: 20010816
Last Updated on STN: 20010924
Entered Medline: 20010920
AB IFN alpha has both antiviral and immunostimulating properties. The ANRS086 Primoferon A Study evaluated in 12 patients with primary HIV infection the tolerance and efficacy of an early and transient administration of **pegylated** IFN alpha, in addition to highly active antiretroviral therapy. Tolerance was good, and this regimen allowed the early control of HIV replication and rapid decay of the viral reservoir. These results support the initiation of comparative studies with **pegylated INF alpha** in primary **HIV** infection.

L7 ANSWER 7 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2002:153875 BIOSIS

DN PREV200200153875
TI Immunologic profile of **HIV-1** infected patients after administration of **pegylated interferon-alpha** -2b (**PEG**-intron.
AU Vigklis, V. (1); Laughlin, M.; Gargalianos, P.; Lazanas, M.; Botsi, C.; Saroglou, G.; Sabatakou, H.; Paraskeva, D.; Stavrianeas, N.; Mavroidi, N.; Glue, P.; Hatzakis, A. (1)
CS (1) Dept. of Hygiene and Epidemiology, Athens Univ. Medical School, Athens Greece
SO AIDS (Hagerstown), (October, 2000) Vol. 14, No. Supplement 4, pp. S19. http://www.aidsonline.com/. print.
Meeting Info.: Fifth International Congress on Drug Therapy in HIV Infection Glasgow, UK October 22-26, 2000
ISSN: 0269-9370.
DT Conference
LA English

L11 ANSWER 1 OF 10 MEDLINE
AN 2002098072 MEDLINE
DN 21686113 PubMed ID: 11827840
TI **Interferon-alpha** in treatment of chronic hepatitis C in co-infected **HIV**-patients in combination with ribavirin and as a pre-load therapy in treatment-naive **HIV**-positive patients. 8th European Conference on Clinical Aspects and Treatment of **HIV** Infection (8th ECCATH), 29-31 October, Athens Greece.
AU Tossing Gudrun
CS ESSEX Pharma GmbH Muenchen, Tannenstr. 15a, D-42653 Solingen, Germany.. gudrun.tossing@essex.de
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH, (2002 Jan 29) 7 (1) 44-6. Journal code: 9517857. ISSN: 0949-2321.
CY Germany: Germany, Federal Republic of
DT Conference; Conference Article; (CONGRESSES)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 20020206
Last Updated on STN: 20020423
Entered Medline: 20020422
AB Though AIDS-related morbidity and mortality are generally decreasing as a result of **highly active antiretroviral therapy** (**HAART**) and prevention of opportunistic infections, dual infection with HCV and HIV leads to an acceleration in the natural course of chronic hepatitis C (cHC) and worsening of associated liver disease and complications. Mortality from co-morbid HCV infection within this population is increasing and has become a major challenge in the management of HIV-related complications. As treatment strategies to fight cHC have been essentially ameliorated within the recent two years in using **pegylated** interferon-alfa2b (**Peg**-IFN-alfa2b) combined with ribavirin, t here is hope that the successful therapeutic outcomes in HCV-mono-infected individuals may be partly translated into benefits for the difficult-to-treat patients with HCV-HIV co-infection. A number of issues arise when beginning HCV treatment during **HAART**, as for instance possible interactions with antiretroviral therapies, increased risk of special side effects, and a compromise in adherence due to the addition of new medication in patients already taking several drugs. On the other hand there is also the chance that **Peg**-IFN-alfa2b fights HIV as well as HCV. First data of pre-load therapy with **Peg**-IFN-alfa2b in treatment-na ve HIV-positive individuals before the initiation of **HAART** have also been presented during the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (8th ECCATH), October 2001 in Athens.

L11 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2002:928015 CAPLUS
DN 137:379981
TI HIV therapy
IN Laughlin, Mark A.; Glue, Paul W.; Stalgis, Carlos O.
PA USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002182179	A1	20021205	US 2000-516673	20000301
PRAI	US 1999-122370P	P	19990302		

US 1999-124304P P 19990312
US 1999-128296P P 19990408

AB Methods for the treatment of treatment-naive as well as treatment-experienced adult and pediatric patients with HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administration of a therapeutically effective amt. of **pegylated** interferon-alfa, e.g., **pegylated** interferon alfa-2b as monotherapy or preferably in assocn. with a therapeutically effective amt. of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amt. of an anti-HIV-1 drug therapy, e.g., **HAART** are disclosed.

L11 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2000:790325 CAPLUS
DN 133:329566
TI **PEGylated interferon-.alpha.**-CCR5 antagonist combination **HIV** therapy
IN Laughlin, Mark A.
PA Schering Corporation, USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066141	A2	20001109	WO 2000-US11634	20000501
	WO 2000066141	A3	20010208		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1175224	A2	20020130	EP 2000-928604	20000501
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010593	A	20020213	BR 2000-10593	20000501
	JP 2002543144	T2	20021217	JP 2000-615025	20000501
	NO 2001005367	A	20020103	NO 2001-5367	20011102
PRAI	US 1999-304897	A2	19990504		
	WO 2000-US11634	W	20000501		

OS MARPAT 133:329566
AB The invention discloses the use of a **PEGylated interferon-.alpha.** and a CCR5 antagonist, further in assocn. with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with an anti-**HIV-1** drug therapy, e.g., **HAART** (**highly active antiretroviral therapy**), for prepn. of a medicament for the treatment of **HIV-1** infections as well as **HIV-1** infections and HCV co-infections in treatment-naive as well as treatment-experienced adult and pediatric patients.

L11 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2000:628016 CAPLUS
DN 133:206775
TI HIV therapy using **pegylated** interferon-alfa alone and in assocn. with anti-HIV-1 drug therapy
IN Laughlin, Mark A.; Glue, Paul W.; Stalgis, Carlos O.

PA Schering Corporation, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000051631	A2	20000908	WO 2000-US5361	20000301
	WO 2000051631	A3	20010118		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2000256211	A2	20000919	JP 2000-55695	20000301
	EP 1034790	A2	20000913	EP 2000-301695	20000302
	EP 1034790	A3	20001213		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-260388	A2	19990302		
	US 1999-268521	A2	19990312		
	US 1999-288358	A2	19990408		
	US 1999-454004	A2	19991203		

AB The uses of **pegylated** interferon-alfa, alone, and in assocn. with an anti-HIV-1 drug therapy, and ribavirin for the prepn. of a medicament for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and hepatitis C virus (HCV) involving comprising a therapeutically effective amt. of **pegylated** interferon-alfa, e.g., **pegylated** interferon alfa-2b as monotherapy or preferably in assocn. with a therapeutically effective amt. of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amt. of an anti-HIV-1 drug therapy, e.g., **HAART** are disclosed.

L11 ANSWER 5 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2003:236115 BIOSIS
DN PREV200300236115
TI Treatment of chronic hepatitis C in **HIV** infected patients (PTS) with **pegylated interferon alpha** 2B (**PEG**-IFN) plus ribavirin (RBV) versus **pegylated interferon alpha** 2B.
AU Cargnel, A. (1); Angeli, E. (1); Mainini, A. (1); Casella, A. (1); Gubertini, G. (1); Giorgi, R. (1); Orlando, G. (1); Duca, P. G.
CS (1) II Dept Infectious Diseases, L. Sacco Hospital, Milan, Italy Italy
SO Journal of Hepatology, (April 2003, 2003) Vol. 38, No. Supplement 2, pp. 132. print.
Meeting Info.: 38th Annual Meeting of the European Association for the Study of the Liver Istanbul, Turkey March 29-April 01, 2003 European Association for the Study of the Liver
. ISSN: 0168-8278.
DT Conference
LA English

L11 ANSWER 6 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2002:618390 BIOSIS
DN PREV200200618390

TI An open, multicenter, randomized trial comparing **pegylated interferon alpha**-2B (**PEG**-IFN) plus ribavirin (RBV) versus **PEG**-IFN for treatment of **HIV**/HCV co-infected patients.
AU Cargnel, Antonietta (1); Angeli, Elena (1); Casella, Alberto (1); Gubertini, Guido (1); Mainini, Annalisa (1); Orlando, Giovanna (1); Duca, Piergiorgio
CS (1) II Dept Infect Diseases, Sacco Hospital, Milan Italy
SO Hepatology, (October, 2002) Vol. 36, No. 4 Part 2, pp. 363A. http://hepatology.aasldjournals.org/scripts/om.dll/serve?action=searchDB&searchDBfor=home&id=jhep. print.
Meeting Info.: 53rd Annual Meeting on the Liver BOSTON, MA, USA November 01-05, 2002
ISSN: 0270-9139.
DT Conference
LA English

L11 ANSWER 7 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2002:566005 BIOSIS
DN PREV200200566005
TI Early response to combination therapy with low-dose **pegylated interferon-alpha** (**Peg**-IFN) 2b and ribavirin for chronic hepatitis C in **HIV**-infected patients.
AU Moreno, L. (1); Quereda, C. (1); Moreno, A. (1); Casado, J. L. (1); Dronda, F. (1); Perez-Elias, M. J. (1); Mateos, M. L. (1); Moreno, S. (1)
CS (1) Ramon y Cajal Hospital, Madrid Spain
SO Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (2001) Vol. 41, pp. 285. print.
Meeting Info.: 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA September 22-25, 2001
DT Conference
LA English
AB Background: Response to conventional **interferon-alpha** has been poor in **HIV** patients (pts) with chronic hepatitis C (hepC). We evaluate the safety and efficacy of **Peg**-IFN and ribavirin (RBV) combined therapy in the treatment of chronic hepC in pts coinfected with **HIV**. Methods: Open, prospective, ongoing study. Pts included had coinfection with HCV and **HIV**, persistently elevated ALT levels, and a liver biopsy showing either portal or bridging fibrosis. Therapy include **Peg**-IFN-alpha 2b (50 mcg weekly) in combination with RBV (800 mg b.i.d) during 12 months. Primary endpoint is sustained virological response (no detectable HCV RNA by PCR) 6 months after end of therapy. Results: 35 pts were included. Baseline characteristics: median **HIV** RNA levels and CD4 count were 1.7 log and 544 cells/mm3. 32 pts were on antiretroviral (ARV) therapy (AZT:11; d4T:21 pts). Median ALT and AST values were 83 and 61, respectively, and median HCV RNA was 9X105 IU/mL (7X104-8X106). Most frequent genotypes include 1a (8), 1b (10), 2a (2), and 3a (11). Fibrosis score was 1,8 (1-3). Evaluation at 24 weeks (n=18 pts). 6 (33.3%) patients are HCV RNA negative, and 10 (55%) patients have normalized transaminases levels. Response at 3rd month predicted response at 6th month (66% vs 8%, p=0,02). Toxic side effects were: influenza-like-illness (88%), tiredness (82%), local inflammatory reaction (28%), headache (20%), citopenies (17%), depression (14%). Treatment had to be discontinued in 5 pts (14%). No apparent interaction in toxicity or efficacy has been observed in pts who are on **HAART**. Median CD4 count has declined to 347 cells/mm3 (264-595). **HIV** RNA has been maintained or decreased in all the pts. Conclusions: Low dose **Peg**-IFN-alpha in combination with RBV is safe in **HIV** pts with chronic hepC, including those who receive ARV drugs. A poor response (33%) has been observed at week 24.

This result suggests the need of use of higher doses in these pts.

L11 ANSWER 8 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2002:520492 BIOSIS
DN PREV200200520492
TI Antiretroviral efficacy of **pegylated**-alpha interferon.
AU Moreno, L. (1); Quereda, C. (1); Moreno, M. E. (1); Moreno, A. (1); Gutierrez, C. (1); Marti-Belda, P. (1); Diz, S. (1); Moreno, S. (1)
CS (1) Ramon y Cajal Hospital, Madrid Spain
SO Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (2001) Vol. 41, pp. 347. print.
Meeting Info.: 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA September 22-25, 2001
DT Conference
LA English
AB Background: It has been suggested that the new formulation of **alpha-interferon**, the **pegylated alpha -interferon**, recently introduced for the treatment of chronic hepatitis C, may have a clinically significant antiretroviral activity. Methods: Prospective, open clinical trial of therapy of chronic hepatitis C in **HIV**-infected subjects with a combination of low-dose **pegylated** interferon (50 micrograms once weekly) and ribavirin (800 mg/d). **HIV** RNA was measured at months 1, 3 and 6. Results: Among 35 patients included in the study, 23 had **HIV** RNA <50 copies/mL and 12 had detectable **HIV** RNA. All the patients with undetectable viral load were on **highly active antiretroviral therapy** (**HAART**) and none developed virological rebound during the 6 months of therapy with **pegylated** interferon. Among the patients with detectable viral load, 3 were naive for antiretroviral therapy and 9, who had developed virological failure, were on stable therapy. The median CD4 in the 12 patients was 551 cells/mm3 (350-729) and the median **HIV** RNA was 3 log copies/mL (1.8-3.6). 75% of patients, after one month of treatment with **pegylated** interferon and ribavirin, had a median viral load decreased of 0.6 log (0.1 to 1.2). In the third month of treatment, the decrease of median viral load had remained of 0.5 log. Two-thirds of the patients had a sustained response through the period of treatment, without modifications of their antiretroviral therapy. Conclusions: Therapy for chronic hepatitis C with a combination of **pegylated** interferon and ribavirin may help control **HIV** viremia both in naive and pretreated subject. Future clinical trials should define the role of **pegylated** interferon in the treatment of **HIV** infection.

L11 ANSWER 9 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2002:153874 BIOSIS
DN PREV200200153874
TI **HIV-1** dynamics in vivo after administration of **pegylated interferon-alpha**-2b (**PEG** -intron.
AU Sypsa, V. (1); Laughlin, M.; Gargalianos, P.; Lazanas, M.; Botsi, C.; Saroglou, G.; Anastassopoulou, C. (1); Sabatakou, H.; Magafas, N.; Stavrianeas, N.; Giannakopoulou, P.; Glue, P.; Hatzakis, A. (1)
CS (1) Dept of Hygiene and Epidemiology, Athens Univ. Medical School, Athens Greece
SO AIDS (Hagerstown), (October, 2000) Vol. 14, No. Supplement 4, pp. S18. http://www.aidsonline.com/. print.
Meeting Info.: Fifth International Congress on Drug Therapy in HIV Infection Glasgow, UK October 22-26, 2000
ISSN: 0269-9370.
DT Conference

LA English

L11 ANSWER 10 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2000129506 EMBASE
TI [Coinfection with the hepatitis C virus and HIV: Current aspects].
CO-INFECTION PAR LE VIRUS DE L'HEPATITE C ET LE VIRUS DE L'IMMUNODEFICIENCE HUMAINE: ASPECTS ACTUELS.
AU Bani-Sadr F.; Perronne C.
CS F. Bani-Sadr, Svc. Maladies Infectieuses/Tropic., Hop. Universitaire Raymond-Poincare, Faculte de Medecine Paris-Ouest, 104, boulevard Raymond-Poincare, 92380 Garches, France
SO Medecine et Maladies Infectieuses, (2000) 30/SUPPL. 1 (43-48).
Refs: 39
ISSN: 0399-077X CODEN: MMAIB5
CY France
DT Journal; Conference Article
FS 004 Microbiology
037 Drug Literature Index
048 Gastroenterology
LA French
SL English; French
AB The treatment of coinfection with the hepatitis C virus (HCV) in **HIV**- infected patients was rarely discussed before the era of the **HIV** protease inhibitors, since the response to monotherapy with **interferon alpha** (**INF.alpha.**) was poor, with a mean prognosis of the **HIV** disease estimated at around ten years. In the present context, monitoring is reconsidered. The **HIV**-associated immunosuppression may be responsible for a false negativity of some serologic tests for HCV. The **HIV**-HCV coinfection increases the risk of maternofoetal transmission of HCV. Studies evaluating the influence of the **HIV** coinfection on the natural history of the HCV infection show its deleterious role. The immune restoration obtained with the **highly active antiretroviral therapies** is not linked with a decrease of the HCV vital load. The **HIV**-HCV coinfection is responsible for a threefold increase of the risk of elevation of seric transaminases when an antiretroviral treatment is given. The immune restoration obtained with an antiretroviral treatment may reveal the HCV infection and favor a rapid aggravation of hepatic histology and evolution toward cirrhosis. HCV-associated complications may become a major factor of morbidity and mortality, leading to the need for an anti-hepatitis C treatment in **HIV**-infected patients. The combination of **INF.alpha.** and ribavirin seems to be the best treatment. Its efficacy and tolerability must be evaluated in **HIV**-infected patients. Drug interactions are likely to occur, and **INF.alpha.**, like ribavirin, may favor CD4 lymphopenia. A new form of **INF.alpha.** with a prolonged half-life (**PEG-INF.alpha.**) seems to be promising. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

L16 ANSWER 1 OF 4 SCISEARCH COPYRIGHT 2003 THOMSON ISI
AN 2001:496512 SCISEARCH
GA The Genuine Article (R) Number: 442BH
TI New therapies for the treatment of AIDS-related Kaposi sarcoma
AU Dezube B J (Reprint)
CS Beth Israel Deaconess Med Ctr, Div Hematol Oncol, 330 Brookline Ave, CC-913, Boston, MA 02215 USA (Reprint); Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA
CYA USA
SO CURRENT OPINION IN ONCOLOGY, (SEP 2000) Vol. 12, No. 5, pp. 445-449. Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 1040-8746.
DT General Review; Journal
LA English
REC Reference Count: 34
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Kaposi sarcoma (KS) is the most common tumor arising in **HIV**-infected patients and is an **AIDS**-defining illness by the Centers for Disease Control guidelines. The clinical course of **AIDS**-related KS is highly variable, ranging from minimal stable disease to explosive growth. Recent advances in the elucidation of the pathogenesis of KS are uncovering many potential targets for KS therapies. Such targets include the processes of angiogenesis and cellular differentiation, sex hormones, and the KS herpesvirus/human herpesvirus-8. With the increasing recognition that effective antiretroviral regimens are associated with both a decreased proportion of new **AIDS**-defining KS cases and a regression in the size of existing KS lesions, most, if not all, KS patients should be advised to take antiretroviral drugs that will maximally decrease **HIV-1** viral load. Five agents are currently approved by the Food and Drug Administration for the treatment of KS: alitretinoin gel for topical administration; and liposomal daunorubicin, liposomal doxorubicin, paclitaxel, and **interferon-alpha** for systemic administration. Many more agents, particularly angiogenesis inhibitors, are in early clinical development. The potential interaction between anti-KS agents and antiretroviral agents needs to be kept in mind. Virtually all patients with KS can derive benefit from the many approved and investigational agents developed through years of collaborative translational and clinical research. Curr Opin Oncol 2000. 12:445-449 (C) 2000 Lippincott Williams & Wilkins, Inc.

L16 ANSWER 2 OF 4 SCISEARCH COPYRIGHT 2003 THOMSON ISI
AN 2001:30994 SCISEARCH
GA The Genuine Article (R) Number: 371RQ
TI Immunologic profile of **HIV-1** infected patients after administration of **pegylated interferon-alpha**-2b (**PEG**-intron)
AU Vigklis V (Reprint); Laughlin M; Gargalianos P; Lazanas M; Botsi C; Saroglou G; Sabatakou H; Paraskeva D; Stavrianeas N; Mavroidi N; Glue P; Hatzakis A
CS Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens, Greece; Schering Plough Res Inst, Kenilworth, NJ USA; G Gennimates Hosp, Athens, Greece; Red Cross Hosp, Athens, Greece; Syggrou Hosp, Athens, Greece; Evangelismos Hosp, Athens, Greece
CYA Greece; USA
SO AIDS, (OCT 2000) Vol. 14, Supp. [4], pp. S19-S19. MA P8. Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 0269-9370.
DT Conference; Journal

LA English
REC Reference Count: 0

L16 ANSWER 3 OF 4 SCISEARCH COPYRIGHT 2003 THOMSON ISI
AN 2001:30993 SCISEARCH
GA The Genuine Article (R) Number: 371RQ
TI **HIV-1** dynamics in vivo after administration of **pegylated interferon-alpha**-2b(**PEG**-intron)
AU Sypsa V (Reprint); Laughlin M; Gargalianos P; Lazanas M; Botsi C; Saroglou G; Anastassopoulou C; Sabatakou H; Magafas N; Stavrianeas N; Giannakopoulou P; Glue P; Hatzakis A
CS Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens, Greece; Schering Plough Res Inst, Kenilworth, NJ USA; G Gennimatas Hosp, Pireas, Greece; Red Cross Hosp, Pireas, Greece; Syggrou Hosp, Athens, Greece; Evangelismos Hosp, Athens, Greece
CYA Greece; USA
SO AIDS, (OCT 2000) Vol. 14, Supp. [4], pp. S18-S18. MA P7.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 0269-9370.
DT Conference; Journal
LA English
REC Reference Count: 1

L16 ANSWER 4 OF 4 SCISEARCH COPYRIGHT 2003 THOMSON ISI
AN 2001:30992 SCISEARCH
GA The Genuine Article (R) Number: 371RQ
TI Safety, tolerability and antiviral pharmacodynamics of **pegylated interferon-alpha** 2b in **HIV-1** infection: a phase I study
AU Hatzakis A (Reprint); Laughlin M; Gargalianos P; Lazanas M; Botsi C; Saroglou G; Glue P
CS Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens, Greece; Schering Plough Res Inst, Kenilworth, NJ USA; G Gennimates Hosp, Pireas, Greece; Tzanion Hosp, Pireas, Greece; Syggrou Hosp, Athens, Greece; Evangelismos Hosp, Athens, Greece
CYA Greece; USA
SO AIDS, (OCT 2000) Vol. 14, Supp. [4], pp. S18-S18. MA P6.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 0269-9370.
DT Conference; Journal
LA English
REC Reference Count: 0

L20 ANSWER 1 OF 17 MEDLINE
TI Development of **pegylated** interferons for the treatment of chronic hepatitis C.
AU Kozlowski A; Charles S A; Harris J M
SO BioDrugs, (2001) 15 (7) 419-29. Ref: 46
Journal code: 9705305. ISSN: 1173-8804.

L20 ANSWER 2 OF 17 MEDLINE
TI [Chronic hepatitis C and HIV. Current therapeutic options]. Chronische Hepatitis C und HIV. Aktuelle therapeutische Optionen.
AU Mauss S
SO MMW FORTSCHRITTE DER MEDIZIN, (2001 Apr 2) 143 Suppl 1 46-9.
Journal code: 100893959. ISSN: 1438-3276.

L20 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2003 ACS
TI Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients
AU Dieterich, Douglas T.
SO Journal of Infectious Diseases (2002), 185(Suppl. 2), S128-S137
CODEN: JIDIAQ; ISSN: 0022-1899

L20 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS
TI Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and **pegylated** IFN.alpha.: Results from the primoferon A (ANRS 086) study
AU Fenton, Kevin A.; Chinouya, Martha; Davidson, Oliver; Copas, Andrew
SO AIDS (London, United Kingdom) (2001), 15(11), 1435-1437
CODEN: AIDSET; ISSN: 0269-9370

L20 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2003 ACS
TI **PEG**-modified lysozyme C and medicinal compositions for the treatment of some serious diseases
IN Veronesi, Paolo Alberto; Rodriguez, Pablo E. A.
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2

L20 ANSWER 6 OF 17 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Hepatitis C and liver fibrosis.
AU Schuppan, D. (1); Krebs, A.; Bauer, M.; Hahn, E. G.
SO Cell Death and Differentiation, (January 2003, 2003) Vol. 10, No. Supplement 1, pp. S59-S67. print.
ISSN: 1350-9047.

L20 ANSWER 7 OF 17 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI A randomized controlled trial of **pegylated-interferon alpha**-2b+ribavirin vs **interferon alpha** -2b+ribavirin in **HIV** co-infected patients.
AU Pol, S. (1); Perronne, C. (1); Carrat, F. (1); Banisadr, F. (1); Morand, P. (1); Lunel, F. (1); Rosenthal, E. (1)
SO Journal of Hepatology, (April 2003, 2003) Vol. 38, No. Supplement 2, pp. 32. print.
Meeting Info.: 38th Annual Meeting of the European Association for the Study of the Liver Istanbul, Turkey March 29-April 01, 2003 European Association for the Study of the Liver
. ISSN: 0168-8278.

L20 ANSWER 8 OF 17 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI **Pegylated interferon alpha** in patients treated from primary **HIV** infection prevents viral rebound during structured treatment interruptions of antiretroviral drugs.

AU Emilie, D. (1); Burgard, M.; Krzysiek, R. (1); Rouzious, C.; Galanaud, P. (1)
SO Journal of Interferon and Cytokine Research, (2002) Vol. 22, No. Supplement 1, pp. S-80. print.
Meeting Info.: Joint Meeting of the International Society for Interferon and Cytokine Research, the International Cytokine Society, the Society for Leukocyte Biology, and the European Cytokine Society on Cytokines and Interferons Turin, Italy October 06-10, 2002 International Society for Interferon and Cytokine Research
. ISSN: 1079-9907.

L20 ANSWER 9 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Hepatitis C virus in human immunodeficiency virus-infected individuals: An emerging comorbidity with significant implications.
AU Gonzalez S.A.; Talal A.H.
SO Seminars in Liver Disease, (2003) 23/2 (149-166).
Refs: 149
ISSN: 0272-8087 CODEN: SLDIEE

L20 ANSWER 10 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Peginterferon-.alpha.-2a (40kD) plus ribavirin: A review of its use in the management of chronic hepatitis C.
AU Keating G.M.; Curran M.P.
SO Drugs, (2003) 63/7 (701-730).
Refs: 89
ISSN: 0012-6667 CODEN: DRUGAY

L20 ANSWER 11 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Treatment of hepatitis C and B virus infection with interferon].
PLACE DES INTERFERONS DANS LE TRAITEMENT DES INFECTIONS PAR LES VIRUS DE L'HEPATITE B ET DE L'HEPATITE C.
AU Cacoub P.; Benhamou Y.
SO Revue de Medecine Interne, (1 Nov 2002) 23/SUPPL. 4 (459s-474s).
Refs: 163
ISSN: 0248-8663 CODEN: RMEIDE

L20 ANSWER 12 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Potential of interferon-.alpha. in solid tumours: Part 2.
AU Santhanam S.; Decatris M.; O'Byrne K.
SO BioDrugs, (2002) 16/5 (349-372).
Refs: 391
ISSN: 1173-8804 CODEN: BIDRF4

L20 ANSWER 13 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI The natural history and antiviral treatment of hepatitis C in haemophilia.
AU Lee C.; Dusheiko G.
SO Haemophilia, (2002) 8/3 (322-329).
Refs: 33
ISSN: 1351-8216 CODEN: HAEMF4

L20 ANSWER 14 OF 17 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV.
AU Puoti M.; Zanni B.; Bruno R.; Airoldi M.; Rossi S.; Roldan E.Q.; El Hamad I.; Moretti F.; Castelli F.; Sacchi P.; Filice G.; Carosi G.
SO HIV Clinical Trials, (2002) 3/4 (324-332).
Refs: 76
ISSN: 1528-4336 CODEN: HCTIA8

L20 ANSWER 15 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI Effects of HCV treatment on **HIV** course. Preliminary results of

the, anrs hc 02-ribavic study: A randomized, controlled trial of **pegylated interferon-alpha** 2b with ribavirin vs **interferon-alpha** 2b with ribavirin for the treatment of chronic HCV in **HIV** co-infection.

AU Banisadr F (Reprint); Carrat F; Pol S; Rosenthal E; Morand P; Lunel F; Perronne C

SO HEPATOLOGY, (OCT 2002) Vol. 36, No. 4, Part 2, Supp. [S], pp. 585A-585A. MA 1688.
Publisher: W B SAUNDERS CO, INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA.
ISSN: 0270-9139.

L20 ANSWER 16 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI

TI An open, multicenter, randomized trial comparing **pegylated interferon alpha**-2b (**PEG**-IFN) plus ribavirin (RBV) versus **PEG**-IFN for treatment of **HIV**/HCV co-infected patients.

AU Cargnel A (Reprint); Angeli E; Casella A; Gubertini G; Mainini A; Orlando G; Duca P

SO HEPATOLOGY, (OCT 2002) Vol. 36, No. 4, Part 2, Supp. [S], pp. 363A-363A. MA 802.
Publisher: W B SAUNDERS CO, INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA.
ISSN: 0270-9139.

L20 ANSWER 17 OF 17 SCISEARCH COPYRIGHT 2003 THOMSON ISI

TI Hepatitis C and human immunodeficiency virus coinfections

AU Dodig M; Tavill A S (Reprint)

SO JOURNAL OF CLINICAL GASTROENTEROLOGY, (NOV-DEC 2001) Vol. 33, No. 5, pp. 367-374.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 0192-0790.

L27 ANSWER 1 OF 73 MEDLINE
TI **Antiretrovirals** plus immunomodulators: didanosine/ **interferon**-alpha **combination** shows promise.
AU Folkers G
SO NIAID AIDS AGENDA, (1996 Jun) 8-9.
Journal code: 9432911.

L27 ANSWER 2 OF 73 MEDLINE
TI Immune-based therapies.
AU Lein B
SO PI PERSPECTIVE, (1995 Dec) (no 17) 16-8.
Journal code: 9102818. ISSN: 1058-7454.

L27 ANSWER 3 OF 73 MEDLINE
TI Safety and efficacy of **interferon**-ribavirin **combination therapy** in HCV-**HIV** coinfected subjects: an early report.
AU Zylberberg H; Benhamou Y; Lagneaux J L; Landau A; Chaix M L; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Brechot C; Pol S
SO GUT, (2000 Nov) 47 (5) 694-7.
Journal code: 2985108R. ISSN: 0017-5749.

L27 ANSWER 4 OF 73 MEDLINE
TI A randomized trial of **interferon alpha therapy** for **HIV** type 1 infection.
AU Haas D W; Lavelle J; Nadler J P; Greenberg S B; Frame P; Mustafa N; St Clair M; McKinnis R; Dix L; Elkins M; Rooney J
SO AIDS RESEARCH AND HUMAN RETROVIRUSES, (2000 Feb 10) 16 (3) 183-90.
Journal code: 8709376. ISSN: 0889-2229.

L27 ANSWER 5 OF 73 MEDLINE
TI Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
AU Dieterich D T
SO AMERICAN JOURNAL OF MEDICINE, (1999 Dec 27) 107 (6B) 79S-84S.
Journal code: 0267200. ISSN: 0002-9343.

L27 ANSWER 6 OF 73 MEDLINE
TI Absence of clinical, virological, and immunological signs of progression in **HIV-1**-infected patients receiving active anti-**interferon-alpha** immunization: a 30-month follow-up report.
AU Gringeri A; Santagostino E; Cusini M; Muca-Perja M; Marinoni A; Mannucci P M; Burny A; Criscuolo M; Lu W; Andrieru J M; Mbika J P; Lachgar A; Fall L S; Chams V; Feldman M; Hermans P; Zagury J F; Bizzini B; Musicco M; Zagury D
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, (1996 Sep) 13 (1) 55-67.
Journal code: 9501482. ISSN: 1077-9450.

L27 ANSWER 7 OF 73 MEDLINE
TI Consensus symposium on combined **antiviral therapy**; overview of **interferon** and IL-2 **combinations** for the **treatment** of **HIV** infection.
AU Sneller M C
SO ANTIVIRAL RESEARCH, (1996 Jan) 29 (1) 105-9.
Journal code: 8109699. ISSN: 0166-3542.

L27 ANSWER 8 OF 73 MEDLINE
TI **Combination therapy** with didanosine and **interferon-alpha** in human **immunodeficiency**

virus-infected patients: results of a phase I/II trial.
AU Kovacs J A; Bechtel C; Davey R T Jr; Falloon J; Polis M A; Walker R E; Metcalf J A; Davey V; Piscitelli S C; Baseler M; Dewar R; Salzman N P; Masur H; Lane H C
SO JOURNAL OF INFECTIOUS DISEASES, (1996 Apr) 173 (4) 840-8.
Journal code: 0413675. ISSN: 0022-1899.

L27 ANSWER 9 OF 73 MEDLINE
TI Zidovudine plus **interferon-alpha** versus zidovudine alone in **HIV**-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
AU Fernandez-Cruz E; Lang J M; Frissen J; Furner V; Chateauvert M; Boucher C A; Dowd P; Stevens J
SO AIDS, (1995 Sep) 9 (9) 1025-35.
Journal code: 8710219. ISSN: 0269-9370.

L27 ANSWER 10 OF 73 MEDLINE
TI Anti-**alpha interferon** immunization: safety and immunogenicity in asymptomatic **HIV** positive patients at high risk of disease progression.
AU Gringeri A; Santagostino E; Mannucci P M; Siracusano L; Marinoni A; Criscuolo M; Carcagno M; Fall L S; M'Bika J P; Bizzini B; +
SO CELLULAR AND MOLECULAR BIOLOGY, (1995 May) 41 (3) 381-7.
Journal code: 9216789. ISSN: 0145-5680.

L27 ANSWER 11 OF 73 MEDLINE
TI **Interferons** in **HIV** and related diseases.
AU Lane H C
SO AIDS, (1994 Sep) 8 Suppl 3 S19-23. Ref: 20
Journal code: 8710219. ISSN: 0269-9370.

L27 ANSWER 12 OF 73 MEDLINE
TI Zidovudine and **interferon-alpha combination therapy** versus zidovudine monotherapy in subjects with symptomatic human **immunodeficiency** virus type 1 infection.
AU Frissen P H; van der Ende M E; ten Napel C H; Weigel H M; Schreij G S; Kauffmann R H; Koopmans P P; Hoepelman A I; de Boer J B; Weverling G J; +
SO JOURNAL OF INFECTIOUS DISEASES, (1994 Jun) 169 (6) 1351-5.
Journal code: 0413675. ISSN: 0022-1899.

L27 ANSWER 13 OF 73 MEDLINE
TI **Combination treatment** with zidovudine, thymosin alpha 1 and **interferon-alpha** in human **immunodeficiency** virus infection.
AU Garaci E; Rocchi G; Perroni L; D'Agostini C; Soscia F; Grelli S; Mastino A; Favalli C
SO INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, (1994) 24 (1) 23-8.
Journal code: 9206491. ISSN: 0940-5437.

L27 ANSWER 14 OF 73 MEDLINE
TI Successful **treatment** of Kaposi's sarcoma with **interferon -alpha** in a patient with acquired **immunodeficiency** syndrome.
AU Yeh T S; Wang C R; Wong W W; Jeng G W; Chen M Y; Liu C Y; Chuang C Y; Chen W Y
SO CHUNG-HUA MIN KUO WEI SHENG WU CHI MIEN I HSUEH TSA CHIH CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, (1993 Feb) 26 (1) 38-43.
Journal code: 8008067. ISSN: 0253-2662.

L27 ANSWER 15 OF 73 MEDLINE
TI **Interferon-alpha**, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I **AIDS** Clinical Trials Group study in patients with Kaposi's sarcoma associated with **AIDS**.
AU Krown S E; Paredes J; Bundow D; Polsky B; Gold J W; Flomenberg N
SO JOURNAL OF CLINICAL ONCOLOGY, (1992 Aug) 10 (8) 1344-51.
Journal code: 8309333. ISSN: 0732-183X.

L27 ANSWER 16 OF 73 MEDLINE
TI Zidovudine-**interferon-alpha combination therapy** in patients with advanced human **immunodeficiency** virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
AU Edlin B R; Weinstein R A; Whaling S M; Ou C Y; Connolly P J; Moore J L; Bitran J D
SO JOURNAL OF INFECTIOUS DISEASES, (1992 May) 165 (5) 793-8.
Journal code: 0413675. ISSN: 0022-1899.

L27 ANSWER 17 OF 73 MEDLINE
TI Phase I/II trials of **alpha-interferon** alone or in **combination** with zidovudine as maintenance **therapy** following induction chemotherapy in the **treatment** of acquired **immunodeficiency** syndrome-related Kaposi's sarcoma.
AU Gill P S
SO SEMINARS IN ONCOLOGY, (1991 Oct) 18 (5 Suppl 7) 53-7.
Journal code: 0420432. ISSN: 0093-7754.

L27 ANSWER 18 OF 73 MEDLINE
TI **Interferon alpha** in the **treatment** of **AIDS**-related Kaposi's sarcoma.
AU Mitsuyasu R T
SO BRITISH JOURNAL OF HAEMATOLOGY, (1991 Oct) 79 Suppl 1 69-73. Ref: 48
Journal code: 0372544. ISSN: 0007-1048.

L27 ANSWER 19 OF 73 MEDLINE
TI Combined **treatment** with zidovudine and lymphoblast **interferon-alpha** in patients with **HIV**-related Kaposi's sarcoma.
AU Baumann R; Tauber M G; Opravil M; Hirschel B; Kinloch S; Chave J P; Pletscher M; Luthy R
SO KLINISCHE WOCHENSCHRIFT, (1991 May 24) 69 (8) 360-7.
Journal code: 2985205R. ISSN: 0023-2173.

L27 ANSWER 20 OF 73 MEDLINE
TI A phase I/II trial of zidovudine, **interferon-alpha**, and granulocyte-macrophage colony-stimulating factor in the **treatment** of human **immunodeficiency** virus type 1 infection.
AU Davey R T Jr; Davey V J; Metcalf J A; Zurlo J J; Kovacs J A; Falloon J; Polis M A; Zunich K M; Masur H; Lane H C
SO JOURNAL OF INFECTIOUS DISEASES, (1991 Jul) 164 (1) 43-52.
Journal code: 0413675. ISSN: 0022-1899.

L27 ANSWER 21 OF 73 MEDLINE
TI A phase I study of recombinant human **interferon-alpha** 2a or human lymphoblastoid **interferon-alpha** n1 and concomitant zidovudine in patients with **AIDS**-related Kaposi's sarcoma.
AU Fischl M A; Uttamchandani R B; Resnick L; Agarwal R; Fletcher M A; Patrone-Reese J; Dearmas L; Chidekel J; McCann M; Myers M

SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, (1991) 4 (1) 1-10.
Journal code: 8812597. ISSN: 0894-9255.

L27 ANSWER 22 OF 73 MEDLINE
TI Virologic and immunologic aspects of acquired immunodeficiency syndrome.
AU Lane H C
SO SURGERY, GYNECOLOGY AND OBSTETRICS, (1990) 171 Suppl 11-8. Ref: 15
Journal code: 0101370. ISSN: 0039-6087.

L27 ANSWER 23 OF 73 MEDLINE
TI **Interferon-alpha** with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired **immunodeficiency** syndrome (**AIDS**).
AU Krown S E; Gold J W; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew B J
SO ANNALS OF INTERNAL MEDICINE, (1990 Jun 1) 112 (11) 812-21.
Journal code: 0372351. ISSN: 0003-4819.

L27 ANSWER 24 OF 73 MEDLINE
TI The enhanced potential use of recombinant **alpha interferon** in the **treatment** of **AIDS**-related Kaposi's sarcoma.
AU Mitsuyasu R T
SO ONCOLOGY NURSING FORUM, (1989 Nov-Dec) 16 (6 Suppl) 5-7.
Journal code: 7809033. ISSN: 0190-535X.

L27 ANSWER 25 OF 73 MEDLINE
TI **Treatment** of patients with chronic type B hepatitis and concurrent human **immunodeficiency** virus infection with a **combination** of **interferon alpha** and azidothymidine: a pilot study.
AU Hess G; Rossol S; Voth R; Gerken G; Ramadori G; Drees N; Meyer zum Buschenfelde K H
SO DIGESTION, (1989) 43 (1-2) 56-9.
Journal code: 0150472. ISSN: 0012-2823.

L27 ANSWER 26 OF 73 MEDLINE
TI Clinical and virological effects of high-dose recombinant **interferon-alpha** in disseminated **AIDS**-related Kaposi's sarcoma.
AU de Wit R; Schattenkerk J K; Boucher C A; Bakker P J; Veenhof K H; Danner S A
SO LANCET, (1988 Nov 26) 2 (8622) 1214-7.
Journal code: 2985213R. ISSN: 0140-6736.

L27 ANSWER 27 OF 73 MEDLINE
TI **Combination** chemotherapy and alpha-**interferon** in the **treatment** of Kaposi's sarcoma associated with acquired immune deficiency syndrome.
AU Shepherd F A; Evans W K; Garvey B; Read S E; Klein M; Fanning M M; Coates R
SO CMAJ, (1988 Oct 1) 139 (7) 635-9.
Journal code: 9711805. ISSN: 0820-3946.

L27 ANSWER 28 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy
AU Landau, Alain; Batisse, Dominique; Piketty, Christophe; Jian, Raymond; Kazatchkine, Michel D.

SO AIDS (London) (2000), 14(12), 1857-1858
CODEN: AIDSET; ISSN: 0269-9370

L27 ANSWER 29 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment
AU Morsica, Giulia; De Bona, Anna; Foppa, Caterina Uberti; Sitia, Giovanni; Finazzi, Renato; Lazzarin, Adriano
SO AIDS (London) (2000), 14(11), 1656-1658
CODEN: AIDSET; ISSN: 0269-9370

L27 ANSWER 30 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Low dose oral **interferon alpha** 2a in **HIV-1** seropositive patients: a double-blind, placebo-controlled trial
AU Wright, Stephen E.; Hutcheson, David P.; Cummins, Joseph M.
SO Biotherapy (Dordrecht, Netherlands) (1998), 11(4), 229-234
CODEN: BTHREW; ISSN: 0921-299X

L27 ANSWER 31 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI A randomized controlled study for the evaluation of the activity of a triple **combination** of zidovudine, thymosin-.alpha.1 and **interferon**-.**alpha**. in **HIV**-infected individuals with CD4 counts between 200 and 500 cells/mm3
AU Garaci, Enrico; Milanese, Giuseppe; Vella, Stefano; Aiuti, Fernando; D'agostini, Cartesio; Francavilla, Ermenegildo; Lazzarin, Adriano; Macri, Giulia; Sarmati, Loredana; Rocchi, Giovanni
SO Antiviral Therapy (1998), 3(2), 103-111
CODEN: ANTHFA; ISSN: 1359-6535

L27 ANSWER 32 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI In vitro and in vivo inhibition of **HIV 1** replication by retroviral transfer of the **interferon** .**alpha**., .beta. or .delta. genes: application to **AIDS** gene **therapy**
AU Leissner, P.; Calenda, V.; Marigliano, M.; Sanhadji, K.; Touraine, J.-L.; Pavirani, A.; Mehtali, M.
SO Annales de Biologie Clinique (1998), 56(2), 167-173
CODEN: ABCLAI; ISSN: 0003-3898

L27 ANSWER 33 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Effect of the **combination** of **interferon**-.alpha. and stavudine on Friend virus infections in (B10.A .times. A.By)F1 mice
AU Sidwell, Robert W.; Warren, Reed P.; Okleberry, Kevin; Burger, Roger A.; Morrey, John D.
SO Journal of Infectious Diseases (1995), 171(Suppl. 2), S93-S98
CODEN: JIDIAQ; ISSN: 0022-1899

L27 ANSWER 34 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Specific inhibition of viral protein synthesis in **HIV**-infected cells in response to **interferon treatment**
AU Coccia, Eliana M.; Krust, Bernard; Hovanessian, Ara G.
SO Journal of Biological Chemistry (1994), 269(37), 23087-94
CODEN: JBCHA3; ISSN: 0021-9258

L27 ANSWER 35 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Restoration of immunological function in asymptomatic HIV-positive patients
IN Coffman, Robert L.
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2

L27 ANSWER 36 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Combined **therapy** with zidovudine, thymosin .alpha.1 and .**alpha**.-**interferon** in the **treatment** of **HIV**-infected patients
AU Garaci, Enrico; Rocchi, Giovanni; Perroni, Luigi; D'Agostini, Cartesio; Soscia, Fabrizio; Mastino, Antonio; Grelli, Sandro; Perno, Carlo Federico; Favalli, Cartesio
SO Comb. Ther. 2 [Proc. Int. Symp.], 2nd (1993), Meeting Date 1992, 235-42. Editor(s): Garaci, Enrico; Goldstein, Allan L. Publisher: Plenum, New York, N. Y.
CODEN: 60EKAQ

L27 ANSWER 37 OF 73 CAPLUS COPYRIGHT 2003 ACS
TI Double-stranded RNAs for combination therapy in the treatment of retroviral diseases
IN Carter, William A.
SO U.S., 6 pp. Cont.-in-part of U.S. Ser. No. 28,823, abandoned.
CODEN: USXXAM

L27 ANSWER 38 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Immunologic profile of **HIV-1** infected patients after **administration** of **pegylated interferon-alpha**-2b (**PEG**-intron.
AU Vigklis, V. (1); Laughlin, M.; Gargalianos, P.; Lazanas, M.; Botsi, C.; Saroglou, G.; Sabatakou, H.; Paraskeva, D.; Stavrianeas, N.; Mavroidi, N.; Glue, P.; Hatzakis, A. (1)
SO AIDS (Hagerstown), (October, 2000) Vol. 14, No. Supplement 4, pp. S19. http://www.aidsonline.com/. print.
Meeting Info.: Fifth International Congress on Drug Therapy in HIV Infection Glasgow, UK October 22-26, 2000
ISSN: 0269-9370.

L27 ANSWER 39 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI **HIV-1** dynamics in vivo after **administration** of **pegylated interferon-alpha**-2b (**PEG**-intron.
AU Sypsa, V. (1); Laughlin, M.; Gargalianos, P.; Lazanas, M.; Botsi, C.; Saroglou, G.; Anastassopoulou, C. (1); Sabatakou, H.; Magafas, N.; Stavrianeas, N.; Giannakopoulou, P.; Glue, P.; Hatzakis, A. (1)
SO AIDS (Hagerstown), (October, 2000) Vol. 14, No. Supplement 4, pp. S18. http://www.aidsonline.com/. print.
Meeting Info.: Fifth International Congress on Drug Therapy in HIV Infection Glasgow, UK October 22-26, 2000
ISSN: 0269-9370.

L27 ANSWER 40 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma.
AU Boulanger, Emmanuelle (1); Agbalika, Felix; Maarek, Odile; Daniel, Marie Therese; Grollet, Laurence; Sigaux, Francois; Oksenhendler, Eric (1)
SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 2, pp. 222b. print.
Meeting Info.: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000 American Society of Hematology
. ISSN: 0006-4971.

L27 ANSWER 41 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI The immunology and immunotherapy of breast cancer: An update.
AU Hadden, J. W. (1)
SO International Journal of Immunopharmacology, (Feb., 1999) Vol. 21, No. 2, pp. 79-101.

ISSN: 0192-0561.

L27 ANSWER 42 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in **lymphocytes**
AU Aquaro, Stefano; Perno, Carlo-Federico (1); Balestra, Emanuela; Balzarini, Jan; Cenci, Alessandra; Francesconi, Mauro; Panti, Stefania; Serra, Franca; Villani, Nicoletta; Calio, Raffaele
SO Journal of Leukocyte Biology, (1997) Vol. 62, No. 1, pp. 138-143.
ISSN: 0741-5400.

L27 ANSWER 43 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Acquisition of syncytium-inducing **HIV-1** strains during **therapy** with zidovudine alone or combined with **alpha interferon** or didanosine.
AU Torres, Y.; Leal, M.; Rey, C.; Medrano, F. J. (1); Sanchez-Quijano, A.; Lissen, E.
SO European Journal of Clinical Microbiology & Infectious Diseases, (1996) Vol. 15, No. 4, pp. 324-327.
ISSN: 0934-9723.

L27 ANSWER 44 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Repair of the in vitro **HIV-1**-induced immunosuppression and blockade of the generation of functional suppressive CD8 cells by anti-**alpha interferon** and anti-Tat antibodies.
AU Lachgar, A. (1); Bernard, J. (1); Bizzini, B. (1); Astgen, A. (1); Le Coq, H. (1); Fouchard, M. (1); Chams, V. (1); Feldman, M.; Burny, A.; Zagury, J. F. (1)
SO Biomedicine & Pharmacotherapy, (1996) Vol. 50, No. 1, pp. 13-18.
ISSN: 0753-3322.

L27 ANSWER 45 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI HIV-1 infection despite immediate combination antiviral therapy after infusion of contaminated white cells.
AU Palmer, Darwin L. (1); Hjelle, Brian L.; Wiley, Clayton A.; Allen, Sarah; Wachsman, William; Mills, Ray G.; Davis, Larry E.; Merlin, Toby L.
SO American Journal of Medicine, (1994) Vol. 97, No. 3, pp. 289-295.
ISSN: 0002-9343.

L27 ANSWER 46 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI **Combination therapy** with zidovudine and low dose **alpha interferon** in **HIV** seropositive patient with rapidly declining CD4 positive **lymphocyte** counts.
AU Jablonowski, H.; Mauss, S.; Knechten, H.; Gansauer, M.; Strohmeyer, G.
SO IXTH INTERNATIONAL CONFERENCE ON AIDS AND THE IVTH STD WORLD CONGRESS.. (1993) pp. 493. IXth International Conference on AIDS in affiliation with the IVth STD World Congress.
Publisher: IXth International Conference on AIDS Berlin, Germany.
Meeting Info.: Meeting Berlin, Germany June 6-11, 1993

L27 ANSWER 47 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI SELECTIVE INHIBITION OF HIV REPLICATION BY ADRIAMYCIN IN MACROPHAGES BUT NOT IN **LYMPHOCYTES**.
AU BERGAMINI A; PERNO C-F; BALZARINI J; CAPOZZI M; MARINELLI L; MILANESE G; PESCE C D; CALIO R; ROCCHI G
SO AIDS RES HUM RETROVIRUSES, (1992) 8 (7), 1239-1247.
CODEN: ARHRE7. ISSN: 0889-2229.

L27 ANSWER 48 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI DIAGNOSIS AND THERAPY OF VIRAL HEPATITIS IN PATIENTS WITH TERMINAL RENAL

INSUFFICIENCY.
AU KOEHLER H; ZYZIK E; GERKEN G; MEYER ZUM BUESCHENFELDE K-H
SO NIEREN- HOCHDRUCKKR, (1991) 20 (8), 355-364.
CODEN: NIHOD9. ISSN: 0300-5224.

L27 ANSWER 49 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI **ALPHA INTERFERON** IN **COMBINATION** WITH AZT AND ACTIVATED **LYMPHOCYTES** FOR THE PREVENTION AND **TREATMENT** OF FELV-INDUCED **IMMUNODEFICIENCY** SYNDROME FELV-FIADS.
AU ZEIDNER N S; MYLES M H; MATHIASON-DUBARD C K; HOVER E A
SO THIRD INTERNATIONAL CONFERENCE ON ANTIVIRAL RESEARCH, BRUSSELS, BELGIUM, APRIL 22-27, 1990. ANTIVIRAL RES. (1990) 0 (SUPPL 1), 45.
CODEN: ARSRDR. ISSN: 0166-3542.

L27 ANSWER 50 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI NATURAL KILLER CELL RESPONSES IN HOMOSEXUAL MEN WITH EARLY HIV INFECTION.
AU CAI Q; HUANG X-L; RAPPOCCIOLO G; RINALDO C R JR
SO J ACQUIRED IMMUNE DEFIC SYNDR, (1990) 3 (7), 669-676.
CODEN: JAISET. ISSN: 0894-9255.

L27 ANSWER 51 OF 73 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI ORGAN-SPECIFIC HEMATOPOIETIC CHANGES INDUCED BY A RECOMBINANT HUMAN INTERFERON-ALPHA IN MICE.
AU ROSENTHIAL G J; STRANAHAN R P III; THOMPSON M; BLAIR P; GERMOLEC D R; COMMENT C E; SCHWAB K; LUSTER M L
SO FUNDAM APPL TOXICOL, (1990) 14 (4), 666-675.
CODEN: FAATDF. ISSN: 0272-0590.

L27 ANSWER 52 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection.
AU De la Blanchardiere A.; Rozenberg F.; Caumes E.; Picard O.; Lionnet F.; Livartowski J.; Coste J.; Sicard D.; Lebon P.; Salmon-Ceron D.
SO Scandinavian Journal of Infectious Diseases, (2000) 32/3 (263-269).
Refs: 37
ISSN: 0036-5548 CODEN: SJIDB7

L27 ANSWER 53 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Efficacy and safety of **combination therapy** with **interferon-.alpha**.2b and ribavirin for chronic hepatitis C in **HIV**-infected patients.
AU Landau A.; Batisse D.; Van Huyen J.P.D.; Piketty C.; Bloch F.; Pialoux G.; Belec L.; Petite J.P.; Weiss L.; Kazatchkine M.D.
SO AIDS, (2000) 14/7 (839-844).
Refs: 28
ISSN: 0269-9370 CODEN: AIDSET

L27 ANSWER 54 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Coinfection with the hepatitis C virus and HIV: Current aspects]. CO-INFECTION PAR LE VIRUS DE L'HEPATITE C ET LE VIRUS DE L'IMMUNODEFICIENCE HUMAINE: ASPECTS ACTUELS.
AU Bani-Sadr F.; Perronne C.
SO Medecine et Maladies Infectieuses, (2000) 30/SUPPL. 1 (43-48).
Refs: 39
ISSN: 0399-077X CODEN: MMAIB5

L27 ANSWER 55 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.
AU Tantisiriwat W.; Tebas P.; Clifford D.B.; Powderly W.G.; Fichtenbaum C.J.
SO Clinical Infectious Diseases, (1999) 28/5 (1152-1154).

Refs: 10
ISSN: 1058-4838 CODEN: CIDIEL

L27 ANSWER 56 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Chemo-immunotherapy of advanced AIDS-related Kaposi's sarcoma.
AU Aversa S.M.L.; Cattelan A.M.; Salvagno L.; Meneghetti F.; Francavilla E.; Sattin A.; Sasset L.; Cadrobbi P.
SO Tumori, (1999) 85/1 (54-59).
Refs: 47
ISSN: 0300-8916 CODEN: TUMOAB

L27 ANSWER 57 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Active anti-**interferon**-.**alpha**. immunization: A European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 **HIV-1**-infected patients (the EURIS study).
AU Gringeri A.; Musicco M.; Hermans P.; Bentwich Z.; Cusini M.; Bergamasco A.; Santagostino E.; Burny A.; Bizzini B.; Zagury D.
SO Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, (1999) 20/4 (358-370).
Refs: 30
ISSN: 1077-9450 CODEN: JDSRET

L27 ANSWER 58 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Decrease of enhanced **interferon** .**alpha**. levels in sera of **HIV**-infected and **AIDS** patients receiving combined **antiretroviral therapy**.
AU Piasecki E.; Knysz B.; Gasiorowski J.; Gladysz A.
SO Archivum Immunologiae et Therapiae Experimentalis, (1999) 47/1 (37-44).
Refs: 50
ISSN: 0004-069X CODEN: AITEAT

L27 ANSWER 59 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy.
AU Albrecht H.; Hoffmann C.; Degen O.; Stoehr A.; Plettenberg A.; Mertenskotter T.; Eggers C.; Stellbrink H.-J.
SO AIDS, (9 Jul 1998) 12/10 (1149-1154).
Refs: 46
ISSN: 0269-9370 CODEN: AIDSET

L27 ANSWER 60 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
AU Van Oijen M.G.C.; Preijers F.W.M.
SO Journal of Drug Targeting, (1998) 5/2 (75-91).
Refs: 108
ISSN: 1061-186X CODEN: JDTAEH

L27 ANSWER 61 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Lymphomatoid granulomatosis: Pathogenesis, pathology and clinical implications.
AU Jaffe E.S.; Wilson W.H.
SO Cancer Surveys, (1997) 30/- (233-248).
Refs: 46
ISSN: 0261-2429 CODEN: CASUD7

L27 ANSWER 62 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Interferons in dermatology].
INTERFERON IN DER DERMATOLOGIE.

AU Stadler R.
SO H+G Zeitschrift fur Hautkrankheiten, (1996) 71/6 (473-481).
ISSN: 0301-0481 CODEN: ZHKRAJ

L27 ANSWER 63 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI The pharmacology of zidovudine.
AU Harlass F.E.
SO Primary Care Update for Ob/Gyns, (1996) 3/2 (58-62).
ISSN: 1068-607X CODEN: PUOGEP

L27 ANSWER 64 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Randomized, placebo-controlled, double-blind study of low-dose oral **interferon-.alpha.** in **HIV-1** antibody positive patients.
AU Hulton M.R.; Levin D.L.; Freedman L.S.
SO Journal of Acquired Immune Deficiency Syndromes, (1992) 5/11 (1084-1090).
ISSN: 0894-9255 CODEN: JAISET

L27 ANSWER 65 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Restriction of **HIV** replication in infected **T cells** and monocytes by **interferon-.alpha.**.
AU Gendelman H.E.; Baca L.; Turpin J.A.; Kalter D.C.; Hansen B.D.; Orenstein J.M.; Friedman R.M.; Meltzer M.S.
SO AIDS Research and Human Retroviruses, (1990) 6/8 (1045-1049).
ISSN: 0889-2229 CODEN: ARHRE7

L27 ANSWER 66 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Interferons in dermatology.
AU Stadler R.; Mayer-da-Silva A.; Bratzke B.; Garbe C.; Orfanos C.
SO Journal of the American Academy of Dermatology, (1989) 20/4 (650-656).
ISSN: 0190-9622 CODEN: JAADDB

L27 ANSWER 67 OF 73 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin.
AU Resnick L.; Markham P.D.; Veren K.; et al.
SO Journal of Infectious Diseases, (1986) 154/6 (1027-1030).
CODEN: JIDIAQ

L27 ANSWER 68 OF 73 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI New therapies for the treatment of AIDS-related Kaposi sarcoma
AU Dezube B J (Reprint)
SO CURRENT OPINION IN ONCOLOGY, (SEP 2000) Vol. 12, No. 5, pp. 445-449.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 1040-8746.

L27 ANSWER 69 OF 73 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI **ALPHA-INTERFERON**-INDUCED **ANTIRETROVIRAL** ACTIVITIES - RESTRICTION OF VIRAL NUCLEIC-ACID SYNTHESIS AND PROGENY VIRION PRODUCTION IN HUMAN-**IMMUNODEFICIENCY**-VIRUS TYPE-1-INFECTED MONOCYTES
AU BACAREGEN L; HEINZINGER N; STEVENSON M; GENDELMAN H E (Reprint)
SO JOURNAL OF VIROLOGY, (NOV 1994) Vol. 68, No. 11, pp. 7559-7565.
ISSN: 0022-538X.

L27 ANSWER 70 OF 73 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI IMMUNE-BASED THERAPEUTICS - SCIENTIFIC RATIONALE AND THE PROMISING APPROACHES TO THE TREATMENT OF THE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTED INDIVIDUAL
AU STEIN D S; TIMPONE J G; GRADON J D; KAGAN J M; SCHNITTMAN S M (Reprint)

SO CLINICAL INFECTIOUS DISEASES, (OCT 1993) Vol. 17, No. 4, pp. 749-771.
ISSN: 1058-4838.

L27 ANSWER 71 OF 73 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI EFFECTS OF ALPHA 2B-**INTERFERON** TO PROGNOSTIC PARAMETERS AND CLINICAL EVENTS IN **HIV** POSITIVE PATIENTS IN STAGES LAS OR ARC
AU PLETTENBERG A (Reprint); NILSSON M; BAHLMANN W; FRANKE C; STOEHR A; ARNDT R; BAUMANN B; LAUFS R; MEIGEL W
SO MEDIZINISCHE KLINIK, (1991) Vol. 86, No. 11, pp. 555-560.

L27 ANSWER 72 OF 73 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI SYNERGISTIC INHIBITION OF HUMAN-**IMMUNODEFICIENCY**-VIRUS TYPE-1 (**HIV-1**) REPLICATION INVITRO BY 1-[(2-HYDROXYETHOXY)METHYL]-6-PHENYLTHIOTHYMINE (HEPT) AND RECOMBINANT **ALPHA INTERFERON**
AU ITO M; BABA M (Reprint); SHIGETA S; DECLERCQ E; WALKER R T; TANAKA H; MIYASAKA T
SO ANTIVIRAL RESEARCH, (1991) Vol. 15, No. 4, pp. 323-330.

L27 ANSWER 73 OF 73 SCISEARCH COPYRIGHT 2003 THOMSON ISI
TI COMBINED **TREATMENT** WITH ZIDOVUDINE AND LYMPHOBLAST **INTERFERON-ALPHA** IN PATIENTS WITH **HIV**-RELATED KAPOSIS-SARCOMA
AU BAUMANN R; TAUBER M G; OPRAVIL M; HIRSCHEL B; KINLOCH S; CHAVE J P; PLETSCHER M; LUTHY R (Reprint)
SO KLINISCHE WOCHENSCHRIFT, (1991) Vol. 69, No. 8, pp. 360-367.